Last week’s hot topic on Multiple Sclerosis was an article titled For MS Patients, New Guidelines for Controlling Rare Brain Infection Risk Under Tysabri Treatment, written by Patricia Inacio.
The article features a review by The European Medicines Agency Pharmacovigilance Risk Assessment Committee (PRAC) on the risk for progressive multifocal leukoencephalopathy (PML) in multiple sclerosis (MS) patients treated with the medicine Tysabri (natalizumab). The issued guidelines have the objective of minimizing patients’ risk.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?